Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.

One in five Albertans live with a lung condition, yet access to critical testing is limited in many rural and remote communities. This lack of access can contribute to delayed diagnosis and less ...

New 2025 testing data shows third- through eighth-graders scored far below 2019 levels in reading. In math, some grades have ...

More than 101 million Indians are currently living with diabetes, with an additional 136 million who are pre-diabetic.

The 79-year-old president underwent another physical exam on Friday morning, which included getting updated COVID-19 and flu ...

UVA Health lung researchers are developing a promising approach to detecting patients at risk of interstitial lung disease ...

If you start to experience symptoms like chest pain, blue lips, or coughing up more than a teaspoon of blood, you should see ...

The FDA granted approval to nerandomilast, now Jascayd, for treating adults with idiopathic pulmonary fibrosis, marking the ...